Bram De Wilde

Bram De Wilde

Auto-generated profile, based on publicly available information

Bram De Wilde

Universitair Hospital Gent, Gent, Belgium

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MPMartin Peifer
Martin Peifer
LFLynnette Fernández-Cuesta
Lynnette Fernández-Cuesta
MSMartin L Sos
Martin L Sos
JGJulie George
Julie George
DSDanila Seidel
Danila Seidel
RTRoman K Thomas
Roman K Thomas

14 October 2015 in Nature
Verified
Journal Article
Closed access
PDF file
MPMartin Peifer
Martin Peifer
FHFalk Hertwig
Falk Hertwig
FRFrederik Roels
Frederik Roels
DDDaniel Dreidax
Daniel Dreidax
MGMoritz Gartlgruber
Moritz Gartlgruber
MFMatthias Fischer
Matthias Fischer

7 December 2018 in Science
Verified
Journal Article
Closed access
PDF file
SASandra Ackermann
Sandra Ackermann
MCMaria Cartolano
Maria Cartolano
BHBarbara Hero
Barbara Hero
AWAnne Welte
Anne Welte
YKYvonne Kahlert
Yvonne Kahlert
MFMatthias Fischer
Matthias Fischer
A systematic look at a childhood tumor: Neuroblastomas—the most common tumor type in infants—develop from fetal nerve cells, and their clinical course is highly variable. Some neuroblastomas are fatal despite treatment, whereas others respond well to treatment and some undergo spontaneous regression without treatment. Ackermann et al. sequenced more than 400 pretreatment neuroblastomas and identified molecular features that characterize the three distinct clinical outcomes. Low-risk tumors lack telomere maintenance mechanisms, intermediate-risk tumors harbor telomere maintenance mechanisms, and high-risk tumors harbor telomere maintenance mechanisms in combination with RAS and/or p53 pathway mutations. Science , this issue p. 1165

1 September 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Gudrun SchleiermacherGudrun Schleiermacher
Gudrun Schleiermacher
NJNiloufar Javanmardi
Niloufar Javanmardi
VBVirginie Bernard
Virginie Bernard
QLQuentin Leroy
Quentin Leroy
JCJulie Cappo
Julie Cappo
TMTommy Martinsson
Tommy Martinsson
Purpose: In neuroblastoma, the ALK receptor tyrosine kinase is activated by point mutations. We investigated the potential role of ALK mutations in neuroblastoma clonal evolution. Methods: We analyzed ALK mutations in 54 paired diagnosis–relapse neuroblastoma samples using Sanger sequencing. When an ALK mutation was observed in one paired sample, a minor mutated component in the other sample was searched for by more than 100,000× deep sequencing of the relevant hotspot, with a sensitivity of 0.17%. Results: All nine ALK-mutated cases at diagnosis demonstrated the same mutation at relapse, in one case in only one of several relapse nodules. In five additional cases, the mutation seemed to be relapse specific, four of which were investigated by deep sequencing. In two cases, no mutation evidence was observed at diagnosis. In one case, the mutation was present at a subclonal level (0.798%) at diagnosis, whereas in another case, two different mutations resulting in identical amino acid changes were detected, one only at diagnosis and the other only at relapse. Further evidence of clonal evolution of ALK-mutated cells was provided by establishment of a fully ALK-mutated cell line from a primary sample with an ALK-mutated cell population at subclonal level (6.6%). Conclusion: In neuroblastoma, subclonal ALK mutations can be present at diagnosis with subsequent clonal expansion at relapse. Given the potential of ALK-targeted therapy, the significant spatiotemporal variation of ALK mutations is of utmost importance, highlighting the potential of deep sequencing for detection of subclonal mutations with a sensitivity 100-fold that of Sanger sequencing and the importance of serial samplings for therapeutic decisions.

4 July 2012 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
LHLukas C. Heukamp
Lukas C. Heukamp
TTTheresa Thor
Theresa Thor
Alexander SchrammAlexander Schramm
Alexander Schramm
KPKatleen De Preter
Katleen De Preter
CKCandy Kumps
Candy Kumps
JSJohannes H Schulte
Johannes H Schulte
Activating anaplastic lymphoma kinase (ALK) mutations were recently detected in most familial and 10% of sporadic neuroblastomas. However, the role of mutated ALK in tumorigenesis remains elusive. We demonstrate that targeted expression of the most frequent and aggressive variant, ALKF1174L, is tumorigenic in mice. Tumors resembled human neuroblastomas in morphology, metastasis pattern, gene expression, and the presence of neurosecretory vesicles as well as synaptic structures. This ALK-driven neuroblastoma mouse model precisely recapitulated the genetic spectrum of the disease. Chromosomal aberrations were syntenic to those in human neuroblastoma, including 17q gain and MYCN oncogene amplification. Targeted ALKF1174L and MYCN coexpression revealed a strong synergism in inducing neuroblastoma with minimal chromosomal aberrations, suggesting that fewer secondary hits are required for tumor induction if both oncoproteins are targeted. Treatment of ALKF1174L transgenic mice with the ALK inhibitor TAE-684 induced complete tumor regression, indicating that tumor cells were addicted to ALKF1174L activity. We conclude that an activating mutation within the ALK kinase domain is sufficient to induce neuroblastoma development, and ALK inhibitors show promise for treating human neuroblastomas harboring ALK mutations.

12 October 2017 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
NRNadine Van Roy
Nadine Van Roy
MLMalaïka Van Der Linden
Malaïka Van Der Linden
BMBjörn Menten
Björn Menten
ADAnnelies Dheedene
Annelies Dheedene
CVCharlotte Vandeputte
Charlotte Vandeputte
KPKatleen De Preter
Katleen De Preter
Purpose: Neuroblastoma (NB) is a heterogeneous disease characterized by distinct clinical features and by the presence of typical copy-number alterations (CNAs). Given the strong association of these CNA profiles with prognosis, analysis of the CNA profile at diagnosis is mandatory. Therefore, we tested whether the analysis of circulating cell-free DNA (cfDNA) present in plasma samples of patients with NB could offer a valuable alternative to primary tumor DNA for CNA profiling. Experimental Design: In 37 patients with NB, cfDNA analysis using shallow whole genome sequencing (sWGS) was compared with arrayCGH analysis of primary tumor tissue. Results: Comparison of CNA profiles on cfDNA showed highly concordant patterns, particularly in high-stage patients. Numerical chromosome imbalances as well as large and focal structural aberrations including MYCN and LIN28B amplification and ATRX deletion could be readily detected with sWGS using a low input of cfDNA. Conclusions: In conclusion, sWGS analysis on cfDNA offers a cost-effective, noninvasive, rapid, robust and sensitive alternative for tumor DNA copy-number profiling in most patients with NB. Clin Cancer Res; 23(20); 6305–14. ©2017 AACR.